11/12/2018 7:39:14 PM
Viking Presents Results From Phase 2 Study Of VK2809 In Patients With NAFLD
10/8/2018 7:09:21 AM
Viking Therapeutics Says Data From In Vivo Study Of VK2809 Presented At Oral Plenary Session At ATA
10/1/2018 7:51:04 AM
William Blair Reiterates Viking Therapeutics, Inc. (VKTX) At Market Perform
10/1/2018 7:05:22 AM
Viking Therapeutics Presents Results From Phase 2 Study Of VK5211; Study Achieves Primary Endpoint
9/20/2018 8:53:59 PM
Viking Therapeutics Prices Public Offering Of 9.50 Mln Shares At $18.50/shr
9/19/2018 4:31:57 PM
Viking Therapeutics Announces Proposed Public Offering Of Common Stock
9/18/2018 7:07:27 AM
Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Study Of VK2809
8/10/2018 7:55:42 AM
William Blair Is Raising Viking Therapeutics, Inc. (VKTX) FY20 Estimate To -0.79 From -0.89
8/10/2018 7:55:29 AM
William Blair Is Increasing Viking Therapeutics, Inc. (VKTX) FY19 Estimate To -0.55 From -0.69
8/10/2018 7:55:17 AM
William Blair Is Increasing Viking Therapeutics, Inc. (VKTX) FY18 Estimate To -0.44 From -0.51
8/10/2018 7:54:42 AM
William Blair Reiterates Viking Therapeutics, Inc. (VKTX) At Outperform
7/17/2018 7:06:17 AM
Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected For Plenary Oral Presentation
6/12/2018 7:05:40 AM
Viking Therapeutics Announces Closing Of Public Offering Of 8.625 Mln Shares
6/7/2018 8:33:48 AM
Viking Therapeutics Announces Pricing Of $67.5 Mln Public Offering Of Common Stock